New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons [0.03%]
西班牙新的COVID-19疫苗接种建议：为下一个季节优化
Pilar Arrazola,María Fernández Prada,Ángel Gil et al.
Pilar Arrazola et al.
Despite high initial vaccination rates, Spain's current COVID-19 vaccination coverage in recommended groups does not meet WHO targets. For the upcoming season, challenges include revising vaccination age, updating risk groups, and unifying ...
[Description of 12 HIV-positive patients who have had the COVID-19 in our area] [0.03%]
[我地区12例感染新型冠状病毒肺炎的艾滋病患者分析]
Josep Cucurull-Canosa,Sonia Vega-Molpeceres,Jorge Alberto Damián-Rodríguez et al.
Josep Cucurull-Canosa et al.
[SARS-CoV-2 infection as trigger multisystem inflammatory syndrome?] [0.03%]
[SARS-CoV-2感染引发全身炎性综合征?]
Sara M Fernández-González,Nerea Varela-Ferreiro,Susana Castro Aguiar et al.
Sara M Fernández-González et al.
Emilia Condes,Jose Ramón Arribas;COVID MADRID-S.P.P.M. group
Emilia Condes
M Angeles Lozano-Parras,Marta Amann-Arévalo,Marta Ciller-Martínez et al.
M Angeles Lozano-Parras et al.
COVID and CARE®. Mobile application for monitoring SARS-CoV-2 positive patients after hospitalization [0.03%]
CARE®新冠患者出院后监测手机应用程序
Cristina Gómez Rebollo,Estefanía Mira Padilla,Francisco Santos Luna et al.
Cristina Gómez Rebollo et al.
Juan Cuadros-González
Juan Cuadros-González
[Monitoring of the rehabilitation therapy of COVID-19 effort dyspnea] [0.03%]
[新冠肺炎疫后劳力型呼吸困难的康复治疗监测]
Lucia Ros Dopico,Yale Tung-Chen,Martín Pilares Barco et al.
Lucia Ros Dopico et al.
Concerns about COVID-19 and tuberculosis in Brazil: Social and public health impacts [0.03%]
关于巴西的COVID-19和结核病的问题：社会和公共健康影响
Victoria Stadler Tasca Ribeiro,João Paulo Telles,Felipe Francisco Tuon
Victoria Stadler Tasca Ribeiro
José Alcamí,Joan Joseph Munné,María Ángeles Muñoz-Fernández et al.
José Alcamí et al.
The uncontrolled progression of the aids epidemic has made the development of an efficacious human immunodeficiency virus (HIV) vaccine a major objective of scientific research. No effective preventive vaccine against HIV is currently avail...